A Case of Lung Adenocarcinoma Harboring a Rare LOC285000-ALK-NCK2 Gene Fusion Identified by Next-Generation Sequencing With Long-Term Response to Crizotinib
Min Zhang, MBBS, Huan Zhou, MM, Dan Liu, MD, PhD and 2 more
JTO Clinical and Research Reports · 2021
doi:10.1016/j.jtocrr.2020.100106 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Most patients with NSCLC, initially sensitive, will develop resistance after a period of time after the application of ALK inhibitors. We present here a rare LOC285000-ALK-NCK2 gene fusion with response to crizotinib treatment; the patient achieved a progression-free survival of 23 months.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.